Precigen
↗Germantown, Maryland, USA
Precigen is a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies. The company utilizes proprietary technology platforms, including UltraCAR-T®, AdenoVerse™, and ActoBiotics®, to develop precision medicines for oncology, autoimmune disorders, and infectious diseases.
Following its rebranding from Intrexon Corporation in 2020, Precigen has focused on transitioning from a platform-based discovery engine to a commercial-stage entity. Its lead asset, PAPZIMEOS (PRGN-2012), recently achieved FDA approval, marking a significant milestone in the company's history and establishing its position in the rare disease and gene therapy markets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$3.9M (2024)
Founded:1998
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$1.1B
Investors:Merck KGaA, Third Rock Ventures, Pharmakon Advisors
STOCK
Exchange:NASDAQ
Ticker:PGEN
Market Cap:$1.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved
Modalities:Cell therapy, Gene therapy, CAR-T, Adenoviral vectors
Active Trials:4
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Precigen ActoBio, Precigen Exemplar, PGEN Therapeutics
Key Partnerships:National Cancer Institute (NCI) - CRADA for PRGN-2009, Merck KGaA - Strategic investment and historical CAR-T collaboration, EVERSANA - Commercialization partner for PAPZIMEOS
COMPETITION
Position:Leader
Competitors:4D Molecular Therapeutics, Abeona Therapeutics, Allogene Therapeutics, Inovio Pharmaceuticals
LEADERSHIP
Key Executives:
Helen Sabzevari, PhD - President and CEO
Harry Thomasian Jr. - Chief Financial Officer
Rutul Shah - Chief Operating Officer
Scientific Founders:Randal J. Kirk
Board Members:Randal J. Kirk (Executive Chairman), Fred Hassan, Jeffrey B. Kindler, Nancy Howell Agee
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Precigen. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.